NCT00508157 - A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Metabolic SyndromeSchizophrenia

Interventions

DRUG

Aripiprazole

Tablets, Oral, 5 to 30 mg, once daily, 16 weeks

DRUG

Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)

Tablets, Oral, According to summary of product characteristics (SmPC)

Trial Locations (30)

1125

Local Institution, Budapest

1160

Local Institution, Brussels

5700

Local Institution, Gyula

8620

Local Institution, Wetzikon

33011

Local Institution, Oviedo

34295

Local Institution, Montpellier

35370

Local Institution, Izmir

41301

Local Institution, Roudnice nad Labem

49100

Local Institution, Corfu

55000

Local Institution, Fains-Véel

59037

Local Institution, Lille

67000

Local Institution, Strasbourg

73300

Local Institution, Chania-Crete

73479

Local Institution, Ellwangen

75013

Local Institution, Paris

75674

Local Institution, Paris

86000

Local Institution, Poitiers

87025

Local Institution, Limoges

97440

Local Institution, Werneck

602 00

Local Institution, Brno

625 00

Local Institution, Brno

736 01

Local Institution, Havířov

500 05

Local Institution, Hradec Králové

100 00

Local Institution, Prague

160 00

Local Institution, Prague

190 00

Local Institution, Prague

750 02

Local Institution, Přerov

08025

Local Institution, Barcelona

08036

Local Institution, Barcelona

08907

Local Institution, Barcelona